Range
- - -
Vol / Avg.
-/0.2K
Div / Yield
-
52 Wk
278.04 - 405.85
Mkt Cap
24.4B
Payout Ratio
-
Open
-
P/E
26.93
EPS
8.84
Shares
65.4M
Outstanding
-
Total Float
-
Genmab is a Copenhagen-based cancer drug developer best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company is the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis) and has several pipeline candidates targeting other oncologic indications and autoimmune diseases.

Related Companies

TickerCompanyChg %Mkt Cap
GNMSFGenmab0%24.4B

Genmab Company Questions & Answers

Q

How do I buy Genmab (GNMSF) stock?

A

You can purchase shares of Genmab (OTC: GNMSF) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Genmab's (GNMSF) main competitors?

A

There are no as such competitors for Genmab.

Q

What is the target price for Genmab?

A

There is no analysis for Genmab

Q

How much is Genmab (GNMSF) stock ?

A

The stock price for Genmab (OTC: GNMSF) is $372.72 last updated Thu May 13 2021 19:33:57 GMT+0000 (Coordinated Universal Time).

Q

When is the next Genmab (GNMSF) dividend?

A

There are no upcoming dividends for Genmab.

Q

When is Genmab (OTC:GNMSF) reporting earnings?

A

There are no earnings for Genmab

Q

When is the upcoming split for GNMSF?

A

There is no upcoming split for Genmab.